Physician profile
Jonathan Daniel Moreno
NPI 1689013351
$5,499.44
in general payments reported to CMS, 2019-2025
12 companies · $2,792 in 2025
The $2,792 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $376 · 2021: $79.46 · 2022: $697 · 2023: $228 · 2024: $754 · 2025: $2,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018 · Consulting Fee: $1,730 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.25 |
| Consulting Fee | $1,730.00 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $1,833.52 | 2025 | Attruby |
| Abiomed | $1,782.15 | 2019-2025 | Impella |
| Abbott Laboratories | $930.52 | 2020-2024 | 2nd Gen Centrimag Primary Console, Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $227.68 | 2024-2025 | Barostim Neo System |
| Scpharmaceuticals INC. | $181.14 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $178.18 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Vifor Pharma, INC. | $122.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40.00 | 2025 | Camzyos |
| Impulse Dynamics (USA) INC. | $29.70 | 2023 | Optimizer |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | |
| Alnylam Pharmaceuticals INC. | $23.33 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.